Monday, 18 April 2011
Population Genetics of Feral Horses: Implications of Behavioral Isolation
Monday, 11 April 2011
Pharmacokinetics of sapropterin in patients with phenylketonuria
The article, Pharmacokinetics of sapropterin in patients with phenylketonuria was about a treatment method found to help treat those with phenylketonuria. Phenylketonuria is an inborn error in amino acids metabolism caused by a deficiency in the enzyme phenylalanine hydroxylase (1). A phenylalanine hydroxylase deficiency leads to high blood phenylalanine levels. Pathogenesis is the process of converting phenylalanine to tyrosine. Phenylketonuria collects in all body fluids, because it cannot be converted into tyrosine. A large amount of phenylalanine is converted into tyrosine where as a small portion is integrated into proteins. Phenylketonuria has a pathway that is blocked which causes blood levels of phenylalanine to be extremely higher than levels of a normal healthy human (2). Phenylalanine is an essential amino acid, meaning the body does not make it and it is essential that one must consume it through nutrition.
Phenylalanine is supposed to be broken down by phenylalanine hydroxylase. During hydroxylation, phenylalanine needs certain cofactors and enzymes to allow for the production of tyrosine to occur (3). For the translation to occur the process must involve phenylalanine hydroxylase, cofactor tetrahydrobiopterin (BH4), and other enzymes like dihydropteridine reductase and 4α-carbinolamine dehydratase to assist in the restoration of tetrahydrobiopterin (4). When phenylketonuria is in question it’s the deficiency of the enzyme phenylalanine hydroxylase that is not present, meaning phenylalanine cannot be further broken down which leads to the increase levels of phenylalanine in blood.
Usually those with phenylketonuria manage their disease with a protein-restricted diet. The difficulty issue with diets is there is often a failure to comply with the routine of the diet. Supplementation of BH4 has been proven to reduce plasma phenylalanine levels for phenylketonuria patients. Neutral amino acid supplementation works off in a reverse method of L-Phenylalanine to induce the inhibition of the amino acids to cross the blood-brain barrier (5). The blood brain barrier allows a competitive inhibition of the uptake of phenylalanine by the neutral amino acids. One supplement that is on the market that many Phenylketonuria patients have chosen to use is Kuvan, which is saproterin dihydrochoride tablets. Sapropterin dihydrochloride is known and one of the first medical therapies along with diet for phenylketonuria (6). In many trials this product has been tested and it has been proven that it helps control blood phenylalanine levels in Phenylketonuria patients (7). Tetrahydrobiopterin (BH4) is that helps in lowering the levels.
Sapropterin dihydrochloride, also referred to as sapropterin is an artificial invention of 6R-tetrahydrobiopterin (6R-BH4), which had been proven to be effective in decreasing the blood phenylalanine levels in patients with phenylketonuria. The purpose of the study in Pharmacokinetics of saproterin in patients with phenylketonuria was to identify the characteristics that influence variability of sapropterin.
The study lasted for twelve weeks with fixed amount of doses given to the patients. Patients with phenylketonuria were allowed to participate in the study if there were at least eight years of age and if they had taken the recommended doses in another study that was prior to this twelve week study. There were a total of 78 patients that were involved in this study. The patients received oral once a day doses of sapropterin (Kuvan) in the amounts of 5, 10 or 20 mg/kg. The results showed that the amount of saproterin needed to lower the levels of phenylalanine was based on the patient’s bodyweight, but for all patients the supplement worked and lowered the levels (8).
The topic of phenylketonuria has become an interest of my over the past semester, because I have been doing research on it for a paper. I began to feel sympathetic for those who have this condition, because it can take over one’s life if not treated at a young age and treatment continue throughout their life. If makes one think how hard their life really is, when you look at someone who just may have it a little harder than you.
References:
1. Ding, Z, P Georgiev, and B Thony. “Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. (Original Article). “ Gene Therapy 13.7 (2006): 587. Academic OneFile. Web.31 Jan. 2011.
2. Tymoczko, John, Jeremy Berg, and Lubert Stryer. Biochemistry: A Short Course. W H
Freeman &Co, 2010. Print.
3. Harding CO. Progress towards cell-directed therapy for phenylketonuria. Clin Genet
2008: 74: 97-104. Blackwell Munksgaard, 2008.
4. Williams, Robin A, Cyril DS Mamotte, and John R Burnett. “ Phenylketonuria: An
Inborn Error of Phenylalanine Metabolism. Clin Biochem Rev. 2008 Februrary;26(1):31-41.
5. Pey, Angel L., et al. “Identification of pharmacological chaperones as potential
therapeutic agents to treat phenylketonuria.” Journal of Clinical Investigation
118.8 (2008):2858+. General OneFile. Web.31 Jan.2011
6. Thompson, Cheryl A. “First drug approved for treatment of phenylketonuria.” American
Journal of Health-System Pharmacy 65.2 (2008): 100. Academic One File.Web.31 Jan. 2011.
7. Rollins, Judy A. “First specific drug therapy approved for the treatment of PKU.”
Pediatric Nursing 34.2 (2008): 182. General OneFile. Web.31 Jan 2011.
8. Feillet, Francois, et al. “Pharmacokinetics of sapropterin in patients with
phenylketonuria.” Clinical Pharmacokinetics 47.12 (2008): 817+. Academic OneFile. Web 4 Apr. 2011.
Amber Dowdy
.
Population Isolates and Ophthalmic Diseases.
This article is discussing the relevance between genetic isolates and ophthalmic diseases. It will mainly focus on population isolates and the role they play in searching for the underlying genes responsible for monogenic and complex heterogeneous eye diseases. For some background information, population isolates are a group of individuals who are known to have descended from the founder of a population. Because of this, they have been able to maintain a relative degree of genetic homogeneity due to geographical and cultural isolation. There have been many gains in better understanding the genetic etiology (the genes responsible for casing disease) of age-related macular degeneration and eye diseases that are similar. However, the etiology of the heritable blinding diseases (e.g. primary open-angle glaucoma and myopia) are still issues at hand that are working with the population isolated theory, to hopefully gain a better understanding. Population isolates are found in both recessive traits and complex traits
Population isolates are effective ways to further investigate recessive traits. A high frequency rate of new mutations occurring within humans makes it conceivable that there is a high prevalence of recessive diseases in some isolated populations. This happens because of random chance; also known as genetic drift. This also explains why some alleles are able to be more common or rare over consecutive generations. An increased risk of recessive diseases is also associated with consanguineous relationships meaning blood relatives (incest). Consanguinity is lower than it was in isolated populations and this has been shown in a Finnish isolate study. In the study there were thirty monogenic (meaning only one gene) recessive disorders that are more frequent there than anywhere else. One account for this may be linked to non-random migration of families clustering in small geographical areas.
Retinoschisis is an X-linked retinal disease related to population isolates. This is described as the worsening visual cavity, radial and peripheral superficial retinal detachment. Cases with highest prevalence were reported in Finland based upon age and sex (88 males) from 31 families. This particular ophthalmic disease is located on the short arm of the X-chromosome leaving insight into three other founder mutations with high prevalence disease in Finland families. Some other noted examples of retinal diseases within consanguineous relationships is complex strabismus and nanophthalmos. Complex strabismus is a misalignment of the eye and varies with gaze direction. Several Saudi Arabian families were studied and reported to have a basis for autosomal recessive complex strabismus. Nanophthalmos is very rare and is described by small axial lengths with high-hypermetropia on three separate loci of the eleventh chromosome. There are two forms of this that exist, autosomal dominant and recessive, and there is evidence of a founder effect in the Faroe Islands.
Population isolates are also effective means for studying complex traits in ophthalmic diseases. Age Related Macular Degeneration (AMD) is one example of many complex traits. AMD is characterized by two forms, wet and dry. Dry makes up on average 80% of AMD with being described as serous detachment of the retinal pigment epithelium (RPE). AMD varies considerably between ethnic groups. There was a link reported between the US and Japanese populations in correlation with the complement factor H gene contributing to nearly half of all cases of AMD.
Another example of complex traits is primary open angle glaucoma which is asymptomatic with gradual progressive loss of peripheral vision. This is also accompanied by having a cupped head of the optic nerve. This particular complex trait is reportedly found in the French-Canadian populations of Quebec. Four families were studied and later concluded to have been carrying four MYOC mutations that were believed to have been derived from the original Quebec settlers. Also, 14 additional families with glaucoma carried eight of the MYOC mutation from these original settlers.
In conclusion, it has been both successful and helpful in using population isolates. We now have a better knowledge of recessive traits as well as complex traits and the role they play in ophthalmic disease. Isolated populations may only allow for the identification for a few major diseases; however these genes are identified more efficiently than those from non isolated populations. Being able to identify founder effects helps simplify the analysis of genetic diseases as well as helps the screening service in any populations.
Marcee Amos
Friday, 8 April 2011
Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes
An article written by Bob Roehr titled, “Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes” shows hope for a possible cure for the HIV virus in the future. HIV has long been perceived as an incurable disease that has killed millions of people throughout the course of history. However, scientists have started to learn how HIV enters the body and from that they are now trying to block the entry site to prevent HIV from taking over.
HIV enters cells in the body by attaching to a special region on a cell called a receptor molecule; in this case the receptor is called CD4. Then the virus attaches itself to a co-receptor molecule called CCR5. Scientists then discovered a mutation to the gene that encodes for CCR5. A mutation is a permanent change in the sequence of DNA in a gene. The mutation (called delta-32) prevents CCR5 from being created. With this said, if an individual inherits only one copy of this gene then they have a less likely chance of contracting HIV and if they do, the disease will play out much slower since they will have fewer CCR5 receptors for the virus to attach to. An individual who inherits the mutant gene from both parents will not have any CCR5 receptors which make it close to impossible for HIV to enter the cell.
When all of this was realized, pharmaceutical companies sought out a way to chemically block the CCR5 receptor thus artificially blocking HIV from entering the cell. With this new insight came the production of a small molecule drug called maraviroc.
I chose this article because before I read this article I only thought that HIV entered the body based on what my teachers told me in health class. Their explanation was that it is spread and enters the body through bodily fluids. I never thought about it past that point at a cellular and molecular level. This article enlightened me and has helped me understand how it enters the body on those levels and I found it extremely fascinating. The thought about a potential cure for the HIV virus will be one of the biggest breakthroughs in medical and genetic history.
Ross Beckner
Monday, 4 April 2011
Pittsburgh researchers single out genes for major depression
Friday, 1 April 2011
RNA Interference used to inhibit Huntington's disease translation
RNA interference is used to prevent the expression of specific genes; hopefully, targeting unique rather than simply abundant sequences. The author’s objective in this article was to use RNA interference to suppress the CAG repeats in the Huntington’s gene that lead to the disease state. This research was initially discouraged as the siRNAs used to originally target genes showed little to no discrimination, as several genes were silenced instead of just the target. However; recent advances have allowed peptide nucleic acid antisense reagents to work with a much higher degree of selectivity than prior studies. The study compares the inhibition of the Huntington’s disease allele with the inhibition of the normal allele and other mRNA’s containing both CAG and CUG repeats.
This study showed that selectivity was not only great in the repeat targeting duplex but that this selectivity could even be further enhanced by specific mutations in which the binding efficiency was reduced. Further it was observed that different RNA duplexes silence gene production in different ways. Duplex 7, which had full complementarity to the mutant allele responsible for Huntington’s disease proved to be the most effective. The RNAi actually decreases the rate of transcription which decreases the prevalence of the mutant phenotype. Lastly the most interesting discovery was that an up-regulation of the wild type Huntington allele resulted when inhibition of the mutant occurred via duplex. This could be a result of the action of the RNAi itself, but most likely is a compensatory mechanism for the inhibition of one of the alleles. Basically in the heterozygote cases when a mutant allele is repressed or inhibited the wild type allele is transcribed, or translated, or both more frequently in order to compensate for the protein shortage. This provides some hope for, not just Huntington’s disease but treatment for any disease caused by an expansion of a repeated three gene sequence in the near future. In conclusion the recent advances in the field have taken a technique that was previously disregarded as too hazardous to a patient’s health and begun to evolve into a specific and targeted technique with the promise of one day treating a series of genetic disorders.
I chose this article because I plan to have a future in drug research and it proposed a treatment for a genetic disease. The entire article was interesting as I did not have much in the way of prior knowledge of RNA interference at all. Further I find it somewhat incredible that RNA, the component use for translation, can also be an inhibitor of the very action the text book teaches as almost its’ sole purpose. Lastly it was interesting to see that even at the DNA level the human body does attempt to compensate whenever it is obstructed, especially in this case. Shutting down or restricting mutant alleles will actually cause the other allele to become more pronounced has huge implications if it applies to more than just this set of genes.
J Harper.